The molecular basis for the presence of two autoimmune diseases occurring simultaneously - Preliminary observations based on computer analysis

Autoimmunity

Volumn 45, Issue 3, 2012, Pages 253-263

  Zakka, Labib R ^a   Reche, Pedro A ^b   Ahmed, A Razzaque ^a  

^a Center for Blistering Diseases   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Epitope Spreading; MHC Class II Genes; Mixed Connective Tissue Disease; Mucous Membrane Pemphigoid; Pemphigus Vulgaris

Indexed keywords

70 KDA POLYPEPTIDE SMALL NUCLEAR RIBONUCLEOPROTEIN; ANTIGEN; AUTOANTIBODY; AUTOANTIGEN; BETA4 ANTIGEN; BULLOUS PEMPHIGOID ANTIGEN 1; BULLOUS PEMPHIGOID ANTIGEN 2; DESMOGLEIN 1; DESMOGLEIN 2; HLA ANTIGEN CLASS 2; PREDNISONE; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; COMPUTER ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; GENETIC ANALYSIS; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; MIXED CONNECTIVE TISSUE DISEASE; MOLECULAR DYNAMICS; MUCOUS MEMBRAINE PEMPHIGOID; PEMPHIGUS VULGARIS; POLYMERASE CHAIN REACTION; SEROLOGY; T LYMPHOCYTE;

AMINO ACID SEQUENCE; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; COMPUTATIONAL BIOLOGY; CYTOSKELETAL PROTEINS; DESMOGLEIN 1; DESMOGLEIN 3; EPITOPES, T-LYMPHOCYTE; HLA-D ANTIGENS; HUMANS; MIXED CONNECTIVE TISSUE DISEASE; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGUS; SEQUENCE ALIGNMENT;

EID: 84858627148     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.632454     Document Type: Article

References (116)

1. Ahmed AR, Graham J, Jordon RE, et al. Pemphigus: current concepts. Ann Intern Med 1980;92:396-405. (Pubitemid 10150476)
2. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet 1999;354:667-672. (Pubitemid 29391440)
3. Lever WF. Pemphigus and pemphigoid. A review of the advances made since 1964. J Am Acad Dermatol 1979;1:2-31. (Pubitemid 11160084)
4. Sami N, Bhol KC, Beutner EH, et al. Simultaneous presence of mucous membrane pemphigoid and pemphigus vulgaris: molecular characterization of both autoantibodies. Clin Immunol 2001;100:219-227.
5. Beutner EH, Jordon RE, Chorzelski TP. The immunopathology of pemphigus and bullous pemphigoid. 1968. J Invest Dermatol 1989;:92-166S; discussion 7S-8S.
6. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000;43:571-591; quiz 91-4.
7. Scully C. A review of common mucocutaneous disorders affecting the mouth and lips. Ann Acad Med Singapore 1999; 28:704-707.
8. Sami N, Ahmed AR. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature. Dermatology 2001;202:293-301. (Pubitemid 32664523)
9. Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 2000;201:290-295. (Pubitemid 32037553)
10. Weissman V, Feuerman EJ, Joshua H, et al. The correlation between the antibody titers in sera of patients with Pemphigus vulgaris and their clinical state. J Invest Dermatol 1978;71:107-109. (Pubitemid 9008951)
11. Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40:167-170. (Pubitemid 29072792)
12. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997;159:2010-2017. (Pubitemid 127484192)
13. Sami N, Yeh SW, Ahmed AR. Blistering diseases in the elderly: diagnosis and treatment. Dermatol Clin 2004;22:73-86. (Pubitemid 38224000)
14. McCuin JB, Hanlon T, Mutasim DF. Autoimmune bullous diseases: diagnosis and management. Dermatol Nurs 2006;18:20-25.
15. Scott JE, Ahmed AR. The blistering diseases. Med Clin North Am 1998;82:1239-1283. (Pubitemid 28512423)
16. Wojnarowska F, Venning VA, Burge SM. Immunobullous Diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology (Seventh Edition). 7th ed. Malden, MA: Blackwell Science Ltd; 2008. p 60.
17. Yunis JJ, Mobini N, Yunis EJ, et al. Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. Proc Natl Acad Sci USA 1994;91:7747-7751. (Pubitemid 24238262)
18. Malik M, Gurcan HM, Ahmed AR. Coexistence of mucous membrane pemphigoid and connective-tissue disease. Clin Exp Dermatol 2009;35:156-159.
19. Hoffman RW, Maldonado ME. Immune pathogenesis of Mixed Connective Tissue Disease: a short analytical review. Clin Immunol 2008;128:8-17.
20. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 2005;31:411-420, v. (Pubitemid 41111545)
21. Swanton J, Isenberg D. Mixed connective tissue disease: still crazy after all these years. Rheum Dis Clin North Am 2005;31:421-436, v. (Pubitemid 41111546)
22. Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984;63:92-107. (Pubitemid 14166821)
23. Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42:899-909. (Pubitemid 29215000)
24. Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976;295:1149-1154.
25. Lundberg I, Hedfors E. Clinical course of patients with anti- RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991;18:1511-1519.
26. Kotajima L, Aotsuka S, Sumiya M, et al. Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of data collected in a nationwide collaborative study in Japan. J Rheumatol 1996;23:1088-1094. (Pubitemid 26196103)
27. Frandsen PB, Kriegbaum NJ, Ullman S, et al. Follow-up of 151 patients with high-titer U1RNP antibodies. Clin Rheumatol 1996;15:254-260.
28. Nimelstein SH, Brody S, McShane D, et al. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980;59:239-248. (Pubitemid 10093114)
29. Ginsburg WW, Conn DL, Bunch TW, et al. Comparison of clinical and serologic markers in systemic lupus erythematosus and overlap syndrome: a review of 247 patients. J Rheumatol 1983;10:235-241. (Pubitemid 13064177)
30. Sanders DY, Huntley CC, Sharp GC. Mixed connective tissue disease in a child. J Pediatr 1973;83:642-645.
31. Singsen BH, Swanson VL, Bernstein BH, et al. A histologic evaluation of mixed connective tissue disease in childhood. Am J Med 1980;68:710-717. (Pubitemid 10096037)
32. Hoffman RW, Cassidy JT, Takeda Y, et al. U1-70-kd autoantibody-positive mixed connective tissue disease in children. A longitudinal clinical and serologic analysis. Arthritis Rheum 1993;36:1599-1602. (Pubitemid 23327759)
33. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu Rev Biochem 1996;65:367-409. (Pubitemid 26250614)
34. Pettersson I, Hinterberger M, Mimori T, et al. The structure of mammalian small nuclear ribonucleoproteins. Identification of multiple protein components reactive with anti- (U1)ribonucleoprotein and anti-Sm autoantibodies. J Biol Chem 1984;259:5907-5914. (Pubitemid 14142735)
35. Combe B, Rucheton M, Graafland H, et al. Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. Clin Exp Immunol 1989;75:18-24. (Pubitemid 19058768)
36. Netter HJ, Guldner HH, Szostecki C, et al. A recombinant autoantigen derived from the human (U1) small nuclear RNP-specific 68-kd protein. Expression in Escherichia coli and serodiagnostic application. Arthritis Rheum 1988;31:616-622.
37. O'Brien RM, Cram DS, Coppel RL, et al. T-cell epitopes on the 70-kDa protein of the (U1)RNP complex in autoimmune rheumatologic disorders. J Autoimmun 1990;3:747-757.
38. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 2009;9:15-27.
39. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001;1:147-153. (Pubitemid 33741968)
40. Malik M, Ahmed AR. Dual diagnosis of pemphigus vulgaris and connective tissue disease. J Am Acad Dermatol 2006;55:699-704. (Pubitemid 44436643)
41. Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf 2007;30:1011-1030. (Pubitemid 350036602)
42. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;2:278-299.
43. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998;16:379-387. (Pubitemid 28287771)
44. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009;18:935-940.
45. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010;10:46-50.
46. Alarcon-Segovia D. Mixed connective tissue disease: some statements. Clin Rheumatol 1982;1:81-83. (Pubitemid 12051204)
47. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989;16:328-334. (Pubitemid 19104571)
48. Barnadas MA, Rubiales MV, Gonzalez MJ, et al. Enzyme-linked immunosorbent assay (ELISA) and indirect immuno-fluorescence testing in a bullous pemphigoid and pemphigoid gestationis. Int J Dermatol 2008;47:1245-1249.
49. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002;30:224-232. (Pubitemid 35351315)
50. Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999;140:351-357. (Pubitemid 29111371)
51. Rashid KA, Gurcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006;126:2631-2636. (Pubitemid 44764047)
52. Bunce M,Welsh K. PCR-SSP typing of HLA class I and class II alleles. In: AB Hahn, GA Land, RM Strothman, editors. ASHI Laboratory Manual. 4 ed. Mt. Laurel, NJ: ASHI Publications; 2000. p 19.
53. Lafuente EM, Reche PA. Prediction of MHC-peptide binding: a systematic and comprehensive overview. Curr Pharm Des 2009;15:3209-3220.
54. Reche PA, Glutting JP, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002;63:701-709. (Pubitemid 34983301)
55. Reche PA, Glutting JP, Zhang H, et al. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004;56:405-419. (Pubitemid 39359226)
56. Reche PA, Keskin DB, Hussey RE, et al. Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes. Med Immunol 2006;5:1.
57. Thoma-Uszynski S, UterW, Schwietzke S, et al. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2006;176:2015-2023. (Pubitemid 43134347)
58. Lin MS, Fu CL, Giudice GJ, et al. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol 2000;115:955-961. (Pubitemid 32037435)
59. Hacker-Foegen MK, Zillikens D, Giudice GJ, et al. T cell receptor gene usage of BP180-specific T lymphocytes from patients with bullous pemphigoid and pemphigoid gestationis. Clin Immunol 2004;113:179-186. (Pubitemid 39296851)
60. Budinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998;102:2082-2089. (Pubitemid 29018814)
61. Lin MS, Swartz SJ, Lopez A, et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997;99:31-40. (Pubitemid 27058291)
62. Wucherpfennig KW, Yu B, Bhol K, et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 1995;92:11935-11939.
63. Riechers R, Grotzinger J, Hertl M. HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris: review of the literature and potential applications for the development of a specific immunotherapy. Autoimmunity 1999;30:183-196. (Pubitemid 29469243)
64. Ahmed AR, Park MS, Tiwari JL, et al. Association of DR4 with pemphigus. Exp Clin Immunogenet 1987;4:8-16. (Pubitemid 17029764)
65. Lombardi ML,MercuroO, Ruocco V, et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J Invest Dermatol 1999;113:107-110.
66. Tong JC, Bramson J, Kanduc D, et al. Modeling the bound conformation of Pemphigus vulgaris-associated peptides to MHC Class II DR and DQ alleles. Immunome Res 2006;2:1.
67. Delgado JC, Hameed A, Yunis JJ, et al. Pemphigus vulgaris autoantibody response is linked to HLA-DQB1*0503 in Pakistani patients. Hum Immunol 1997;57:110-119. (Pubitemid 28020908)
68. Loiseau P, Lecleach L, Prost C, et al. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun 2000;15:67-73. (Pubitemid 32289464)
69. Miyagawa S, Higashimine I, Iida T, et al. HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese. J Invest Dermatol 1997;109:615-618. (Pubitemid 27465913)
70. Lee E, Lendas KA, Chow S, et al. Disease relevant HLA class II alleles isolated by genotypic, haplotypic, and sequence analysis in North American Caucasians with pemphigus vulgaris. Hum Immunol 2006;67:125-139. (Pubitemid 43673911)
71. Tron F, Gilbert D, Mouquet H, et al. Genetic factors in pemphigus. J Autoimmun 2005;24:319-328. (Pubitemid 40775856)
72. Gazit E, Loewenthal R. The immunogenetics of pemphigus vulgaris. Autoimmun Rev 2005;4:16-20. (Pubitemid 40126367)
73. Ahmed AR, Wagner R, Khatri K, et al. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 1991;88:5056-5060. (Pubitemid 21914682)
74. Sinha AA, Brautbar C, Szafer F, et al. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 1988;239:1026-1029. (Pubitemid 18094171)
75. Loewenthal R, Slomov Y, Gonzalez-Escribano MF, et al. Common ancestral origin of pemphigus vulgaris in Jews and Spaniards: a study using microsatellite markers. Tissue Antigens 2004;63:326-334. (Pubitemid 38406693)
76. Glorio R, Rodriguez Costa G, Haas R, et al. HLA haplotypes and class II molecular alleles in Argentinian patients with pemphigus vulgaris. J Cutan Med Surg 2002;6:422-426. (Pubitemid 35283407)
77. Brick C, Belgnaoui FZ, Atouf O, et al. Pemphigus and HLA in Morocco. Transfus Clin Biol 2007;14:402-406. (Pubitemid 350217075)
78. Delgado JC, Yunis DE, Bozon MV, et al.MHCclass II alleles and haplotypes in patients with pemphigus vulgaris from India. Tissue Antigens 1996;48:668-672. (Pubitemid 27019691)
79. Carcassi C, Cottoni F, Floris L, et al. HLA haplotypes and class II molecular alleles in Sardinian and Italian patients with pemphigus vulgaris. Tissue Antigens 1996;48:662-667. (Pubitemid 27019690)
80. Gonzalez-Escribano MF, Jimenez G, Walter K, et al. Distribution of HLA class II alleles among Spanish patients with pemphigus vulgaris. Tissue Antigens 1998;52:275-278. (Pubitemid 28434521)
81. Hoffman RW, Rettenmaier LJ, Takeda Y, et al. Human autoantibodies against the 70-kd polypeptide of U1 small nuclear RNP are associated with HLA-DR4 among connective tissue disease patients. Arthritis Rheum 1990;33:666-673. (Pubitemid 20166568)
82. Genth E, Zarnowski H, Mierau R, et al. HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. Ann Rheum Dis 1987;46:189-196. (Pubitemid 17035448)
83. Kaneoka H, Hsu KC, Takeda Y, et al. Molecular genetic analysis of HLA-DR and HLA-DQ genes among anti-U1-70-kd autoantibody positive connective tissue disease patients. Arthritis Rheum 1992;35:83-94.
84. Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Arthritis Rheum 1998;41:768-777. (Pubitemid 28225777)
85. Black CM, Maddison PJ, Welsh KI, et al. HLA and immunoglobulin allotypes in mixed connective tissue disease. Arthritis Rheum 1988;31:131-134. (Pubitemid 18078246)
86. Hoffman RW, Sharp GC, Deutscher SL. Analysis of anti-U1 RNA antibodies in patients with connective tissue disease. Association with HLA and clinical manifestations of disease. Arthritis Rheum 1995;38:1837-1844. (Pubitemid 26010286)
87. Smolen JS, Klippel JH, Penner E, et al. HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens. Ann Rheum Dis 1987;46:457-462. (Pubitemid 17129918)
88. Ruuska P, Hameenkorpi R, Forsberg S, et al. Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Ann Rheum Dis 1992;51:52-55.
89. Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA-DQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA 1996;93:8569-8571. (Pubitemid 26269600)
90. Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001;145:406-414.
91. Carrozzo M, Fasano ME, Broccoletti R, et al. HLA-DQB1 alleles in Italian patients with mucous membrane pemphigoid predominantly affecting the oral cavity. Br J Dermatol 2001;145:805-808. (Pubitemid 33078353)
92. Oyama N, Setterfield JF, Powell AM, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006;154:90-98. (Pubitemid 43381326)
93. Redman RS, Thorne EG. Cicatricial pemphigoid in a patient with systemic lupus erythematosus. Arch Dermatol 1981;117:109-110. (Pubitemid 11138504)
94. Spigel GT, Winkelmann RK. Cicatricial pemphigoid and rheumatoid arthritis. Arch Dermatol 1978;114:415-417. (Pubitemid 8324610)
95. Peyri J, Servitje O, Ribera M, et al. Cicatricial pemphigoid in a patient with rheumatoid arthritis treated with D-penicillamine. J Am Acad Dermatol 1986;14:681. (Pubitemid 16167357)
96. Spigel GT. Association of cicatricial pemphigoid and rheumatoid arthritis. Arch Dermatol 1979;115:108-109. (Pubitemid 9243645)
97. Malik M, Ahmed AR. Concurrence of systemic lupus erythematosus and pemphigus: coincidence or correlation? Dermatology 2007;214:231-239. (Pubitemid 46457609)
98. Chan HL. Pemphigus vulgaris associated with systemic lupus erythematosus. Int J Dermatol 1999;38:948.
99. Kuchabal DS, Kuchabal SD, Pandit AM, et al. Pemphigus vulgaris associated with systemic lupus erythematosus. Int J Dermatol 1998;37:636-638. (Pubitemid 28389336)
100. Fong PH, Chan HL. Systemic lupus erythematosus with pemphigus vulgaris. Arch Dermatol 1985;121:26-27. (Pubitemid 16225018)
101. Russell JG. Pemphigus, Sjogren's syndrome and mucosal pigmentation. Acta Stomatol Int 1987;8:25-29.
102. Shapiro M, Jimenez S, Werth VP. Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol 2000;42:297-299. (Pubitemid 30469635)
103. Nanda A, Kapoor MM, Dvorak R, et al. Coexistence of pemphigus vulgaris with systemic lupus erythematosus. Int J Dermatol 2004;43:393-394. (Pubitemid 38714609)
104. Somorin AO, Agbakwu SN, Nwaefuna A. Systemic lupus erythematosus and pemphigus vulgaris preceded by depressive psychosis. Cent Afr J Med 1981;27:12-14. (Pubitemid 11150704)
105. Hidalgo-Tenorio C, Sabio-Sanchez JM, Tercedor-Sanchez J, et al. Pemphigus vulgaris and systemic lupus erythematosus in a 46-y-old man. Lupus 2001;10:824-826. (Pubitemid 34007899)
106. Hertl M, Karr RW, Amagai M, et al. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:388-392. (Pubitemid 28158655)
107. McCluskey J, Farris AD, Keech CL, et al. Determinant spreading: lessons from animal models and human disease. Immunol Rev 1998;164:209-229. (Pubitemid 28438410)
108. Mitchison NA. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1971;1:18-27.
109. Lake P, Mitchison NA. Regulatory mechanisms in the immune response to cell-surface antigens. Cold Spring Harb Symp Quant Biol 1977;41 Pt 2:589-595.
110. Mamula MJ. Lupus autoimmunity: from peptides to particles. Immunol Rev 1995;144:301-314.
111. Mamula MJ, Janeway CA, Jr. Do B cells drive the diversification of immune responses? Immunol Today 1993; 14:151-152; discussion 3-4.
112. Roth R, Gee RJ, Mamula MJ. B lymphocytes as autoantigen-presenting cells in the amplification of autoimmunity. Ann NY Acad Sci 1997;815:88-104. (Pubitemid 27309491)
113. Lehmann PV, Forsthuber T, Miller A, et al. Spreading of T-cell autoimmunity to cryptic determinants of an auto-antigen. Nature 1992;358:155-157.
114. Chan LS, Vanderlugt CJ, Hashimoto T, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 1998;110:103-109. (Pubitemid 28105841)
115. Chan LS, Soong HK, Foster CS, et al. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA 1991;266:1543-1546.
116. Paisansinsup T, Deshmukh US, Chowdhary VR, et al. HLA class II influences the immune response and antibody diversification to Ro60/Sjogren's syndrome-A: heightened antibody responses and epitope spreading in mice expressing HLA-DR molecules. J Immunol 2002;168:5876-5884. (Pubitemid 34556176)